Piper Jaffray Downgrades Acadia Pharmaceuticals (ACAD) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Acadia Pharmaceuticals (ACAD) Bullish Stance Reiterated at Cowen; All Eyes on PDP PDUFA, ADP Enrollment
November 6, 2015 12:00 PM ESTCowen analyst Ritu Baral reiterated an Outperform rating and $50 price target on Acadia Pharmaceuticals (NASDAQ: ACAD) following Q3 results with all eyes on PDP PDUFA and ADP enrollment.
Baral commented, "ACAD reported 3Q15 earnings and elaborated on initial steps for upcoming commercial... More
Acadia Pharma (ACAD) Tops Q3 EPS by 1c
November 5, 2015 4:13 PM ESTAcadia Pharma (NASDAQ: ACAD) reported Q3 EPS of ($0.39), $0.01 better than the analyst estimate of ($0.40).
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
... More